

BLA 761208

## CORRECTED BLA ACCELERATED APPROVAL

Seagen Inc.  
Attention: Ling Zheng, PhD, MS, RAC  
Associate Director, Regulatory Affairs  
21823 30th Drive, SE  
Bothell, WA 98021

Dear Dr. Zheng:

Please refer to your biologics license application (BLA) dated and received February 10, 2021, and your amendments, submitted under section 351(a) of the Public Health Service Act for Tivdak (tisotumab vedotin-tftv) for injection, for intravenous use.

We also refer to our accelerated approval letter dated September 20, 2021, which contained the following error:

The following postmarketing commitments were omitted from the letter:

- 4131-6 Implement (b) (4) monitoring (b) (4) of tisotumab vedotin drug product and update module 3.2.P.3.4 of the BLA with (b) (4) as a Critical Process Parameter.
- 4131-7 Implement a validated dye ingress method for container closure integrity testing with the sensitivity to detect breaches  $\leq$  (b) (4)  $\mu\text{m}$  that could allow microbial ingress.

This corrected action letter incorporates the inclusion of the above postmarketing commitments. The effective action date will remain September 20, 2021, the date of the original letter.

### **LICENSING**

We are issuing Department of Health and Human Services U.S. License No. 2257 to Seagen Inc., Bothell, Washington, under the provisions of section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product Tivdak (tisotumab vedotin-tftv). Tivdak is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

### **MANUFACTURING LOCATIONS**

Under this license, you are approved to manufacture tisotumab antibody intermediate at (b) (4) and tisotumab vedotin drug substance (b) (4). The SGD-1006 intermediate will be manufactured (b) (4). The final formulated product will be manufactured, filled, and packaged (b) (4) and labeled and packaged (b) (4). You may label your product with the proprietary name Tivdak and will market it in 40 mg single-dose vials for injection.

### **DATING PERIOD**

The dating period for Tivdak shall be 36 months from the date of manufacture when stored at  $5 \pm 3^{\circ}\text{C}$ . The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at  $\leq (b) (4)^{\circ}\text{C}$ . The dating period for your antibody intermediate shall be (b) (4) months from the date of manufacture when stored at  $\leq (b) (4)^{\circ}\text{C}$ .

Results of ongoing stability should be submitted throughout the dating period, as they become available, including the results of stability studies from the first three production lots.

### **FDA LOT RELEASE**

You are not currently required to submit samples of future lots of Tivdak to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Tivdak, or in the manufacturing facilities, will require the submission of information to your biologics license application for our review and written approval, consistent with 21 CFR 601.12.

### **APPROVAL AND LABELING**

We have completed our review of this application, as amended. It is approved under the provisions of accelerated approval regulations (21 CFR 601.41), effective on the date of this letter, for use as recommended in the enclosed agreed-upon approved labeling.

This BLA provides for the use of Tivdak for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced accelerated approval regulations.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide). Information on submitting SPL files using eLIST may be found in the draft guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* (October 2009).<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

### **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* (February 2020, Revision 7). For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761208.**” Approval of this submission by the FDA is not required before the labeling is used.

### **ADVISORY COMMITTEE**

Your application for Tivdak was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> When final, this guidance will represent FDA’s current thinking on this topic. We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

## **ACCELERATED APPROVAL REQUIREMENTS**

Products approved under the accelerated approval regulations, 21 CFR 601.41, require further adequate and well-controlled clinical trials to verify and describe clinical benefit. You are required to conduct such clinical trials with due diligence. If postmarketing clinical trials fail to verify clinical benefit or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 601.43(b), withdraw this approval. We remind you of your postmarketing requirement specified in your submission dated August 20, 2021. This requirement, along with required completion dates, is listed below.

- 4131-1 Conduct the clinical trial innovaTV 301 titled, “Tisotumab Vedotin versus Chemotherapy in Recurrent or Metastatic Cervical Cancer” and provide the final overall survival (OS) and progression-free survival (PFS) analyses to describe and verify the clinical benefit of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Trial Completion: 05/2024

Final Report Submission: 11/2024

Submit clinical protocols to your IND 135476 for this product. In addition, under 21 CFR 601.70 you should include a status summary of each requirement in your annual report to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial.

Submit final reports to this BLA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated “**Subpart E Postmarketing Requirement(s).**”

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are deferring submission of your pediatric studies, as described below because this product is ready for approval for use in adults, and pre-clinical studies to inform clinical studies in pediatric patients have not been completed.

Your deferred pediatric studies required under section 505B(a) of the Federal Food, Drug, and Cosmetic Act are required postmarketing studies. The status of these

**U.S. Food and Drug Administration**  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

postmarketing studies must be reported annually according to 21 CFR 601.28 and section 505B(a)(4)(C) of the Federal Food, Drug, and Cosmetic Act. These required studies are listed below.

- 4131-2 Conduct a pre-clinical study in pediatric-specific pre-clinical models with input from recognized key opinion leaders in pediatric oncology to support the conduct of clinical investigations of tisotumab vedotin in pediatric tumors.

Draft Protocol Submission: 03/2022  
Final Protocol Submission: 06/2022  
Study Completion: 03/2023  
Final Report Submission: 06/2023

- 4131-3 Conduct a clinical investigation of the dose, tolerability, and preliminary evidence of activity of tisotumab vedotin in pediatric patients with cancer(s) in which tissue factor is a relevant therapeutic target.

Draft Protocol Submission: 06/2024  
Final Protocol Submission: 01/2025  
Study Completion: 06/2029  
Final Report Submission: 12/2029

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.<sup>[1]</sup>

Submit the protocol(s) to your IND 135476, with a cross-reference letter to this BLA. Reports of these required pediatric postmarketing studies must be submitted as a biologics license application (BLA) or as a supplement to your approved BLA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

### **POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitments:

- 4131-4 To perform a real-time leachable study for tisotumab vedotin drug product in its commercial container closure system to detect, identify,

---

<sup>[1]</sup> See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019)*.

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

**U.S. Food and Drug Administration**

Silver Spring, MD 20993

[www.fda.gov](http://www.fda.gov)

and quantify potential organic, non-volatile, volatile, and semi-volatile species, and metals through the end of shelf life. The final study reports and risk evaluation will be submitted to the BLA.

The timetable you submitted on June 28, 2021, states that you will conduct this study according to the following schedule:

Final Report Submission: 12/2024

- 4131-5 To develop, characterize, validate, and implement functional activity assay(s) with appropriately justified acceptance criteria to control for Fc effector functions of tisotumab vedotin drug substance at release. The final study results, analytical procedures, method validation reports, and updates to the drug substance release specification will be submitted to the BLA per 21 CFR 601.12.

The timetable you submitted on June 28, 2021, states that you will conduct this study according to the following schedule:

Final Report Submission: 11/2022

- 4131-6 Implement (b) (4) monitoring (b) (4) of tisotumab vedotin drug product and update module 3.2.P.3.4 of the BLA with (b) (4) as a Critical Process Parameter.

The timetable you submitted on July 9, 2021, states that you will conduct this study according to the following schedule:

Final Report Submission: 12/2022

- 4131-7 Implement a validated dye ingress method for container closure integrity testing with the sensitivity to detect breaches  $\leq$  (b) (4)  $\mu\text{m}$  that could allow microbial ingress.

The timetable you submitted on July 13, 2021, states that you will conduct this study according to the following schedule:

Final Report Submission: 10/2021

Submit clinical protocols to your IND 135476 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including

supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

## **PROMOTIONAL MATERIALS**

Under 21 CFR 601.45, you are required to submit, during the application pre-approval review period, all promotional materials, including promotional labeling and advertisements, that you intend to use in the first 120 days following marketing approval (i.e., your launch campaign). If you have not already met this requirement, you must immediately contact the Office of Prescription Drug Promotion (OPDP) at (301) 796-1200. Please ask to speak to a regulatory project manager or the appropriate reviewer to discuss this issue.

As further required by 21 CFR 601.45, submit all promotional materials that you intend to use after the 120 days following marketing approval (i.e., your post-launch materials) at least 30 days before the intended time of initial dissemination of labeling or initial publication of the advertisement. We ask that each submission include a detailed cover letter together with three copies each of the promotional materials, annotated references, and approved Prescribing Information, Medication Guide, and Patient Package Insert (as applicable).

For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format- Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

## **REPORTING REQUIREMENTS**

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80).

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

---

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
10903 New Hampshire Avenue, Bldg. 51, Room 4207  
Silver Spring, MD 20903

### **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call David Nartey, Regulatory Project Manager, at 301-796-4079.

Sincerely,

*{See appended electronic signature page}*

Julia Beaver, MD  
Deputy Director (Acting)  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

#### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Medication Guide
- Carton and Container Labeling



-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JULIA A BEAVER  
09/22/2021 02:46:27 PM